Product Description: Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation[1][2].
Applications: COVID-19-immunoregulation
Formula: C17H11ClN2O2S
References: [1]Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4(1):10-14./[2]Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644.
CAS Number: 58433-11-7
Molecular Weight: 342.80
Research Area: Cancer; Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: COX
Deutsch
English
